ERAS
Price
$2.76
Change
-$0.10 (-3.50%)
Updated
Nov 19 closing price
Capitalization
814.25M
119 days until earnings call
Intraday BUY SELL Signals
FHTX
Price
$5.01
Change
+$0.15 (+3.09%)
Updated
Nov 20, 10:53 AM (EDT)
Capitalization
274.84M
105 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ERAS vs FHTX

Header iconERAS vs FHTX Comparison
Open Charts ERAS vs FHTXBanner chart's image
Erasca
Price$2.76
Change-$0.10 (-3.50%)
Volume$2.05M
Capitalization814.25M
Foghorn Therapeutics
Price$5.01
Change+$0.15 (+3.09%)
Volume$100
Capitalization274.84M
ERAS vs FHTX Comparison Chart in %
ERAS
Daily Signal:
Gain/Loss:
FHTX
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
ERAS vs. FHTX commentary
Nov 20, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ERAS is a Hold and FHTX is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Nov 20, 2025
Stock price -- (ERAS: $2.77 vs. FHTX: $4.86)
Brand notoriety: ERAS and FHTX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ERAS: 113% vs. FHTX: 57%
Market capitalization -- ERAS: $814.25M vs. FHTX: $274.84M
ERAS [@Biotechnology] is valued at $814.25M. FHTX’s [@Biotechnology] market capitalization is $274.84M. The market cap for tickers in the [@Biotechnology] industry ranges from $106.82B to $0. The average market capitalization across the [@Biotechnology] industry is $2.12B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ERAS’s FA Score shows that 1 FA rating(s) are green whileFHTX’s FA Score has 0 green FA rating(s).

  • ERAS’s FA Score: 1 green, 4 red.
  • FHTX’s FA Score: 0 green, 5 red.
According to our system of comparison, ERAS is a better buy in the long-term than FHTX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ERAS’s TA Score shows that 3 TA indicator(s) are bullish while FHTX’s TA Score has 6 bullish TA indicator(s).

  • ERAS’s TA Score: 3 bullish, 5 bearish.
  • FHTX’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, FHTX is a better buy in the short-term than ERAS.

Price Growth

ERAS (@Biotechnology) experienced а +4.34% price change this week, while FHTX (@Biotechnology) price change was +7.28% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -2.19%. For the same industry, the average monthly price growth was -5.74%, and the average quarterly price growth was +63.93%.

Reported Earning Dates

ERAS is expected to report earnings on Mar 19, 2026.

FHTX is expected to report earnings on Mar 05, 2026.

Industries' Descriptions

@Biotechnology (-2.19% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ERAS($814M) has a higher market cap than FHTX($275M). ERAS YTD gains are higher at: 10.159 vs. FHTX (2.966). FHTX has higher annual earnings (EBITDA): -88.7M vs. ERAS (-135.93M). ERAS has more cash in the bank: 301M vs. FHTX (199M). FHTX has less debt than ERAS: FHTX (23.7M) vs ERAS (49.4M). FHTX has higher revenues than ERAS: FHTX (24.2M) vs ERAS (0).
ERASFHTXERAS / FHTX
Capitalization814M275M296%
EBITDA-135.93M-88.7M153%
Gain YTD10.1592.966343%
P/E RatioN/AN/A-
Revenue024.2M-
Total Cash301M199M151%
Total Debt49.4M23.7M208%
TECHNICAL ANALYSIS
Technical Analysis
ERASFHTX
RSI
ODDS (%)
Bearish Trend 1 day ago
84%
N/A
Stochastic
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
86%
Momentum
ODDS (%)
Bullish Trend 1 day ago
83%
Bullish Trend 1 day ago
84%
MACD
ODDS (%)
Bullish Trend 1 day ago
88%
Bullish Trend 1 day ago
90%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
82%
Bullish Trend 1 day ago
88%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
80%
Bullish Trend 1 day ago
83%
Advances
ODDS (%)
Bullish Trend 4 days ago
80%
Bullish Trend 3 days ago
86%
Declines
ODDS (%)
Bearish Trend 1 day ago
87%
Bearish Trend 17 days ago
86%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
83%
Bullish Trend 1 day ago
90%
Aroon
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
89%
View a ticker or compare two or three
Interact to see
Advertisement
ERAS
Daily Signal:
Gain/Loss:
FHTX
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
IVNQX50.730.28
+0.56%
Invesco Nasdaq 100 Index R6
FUNYX39.33N/A
N/A
Victory Pioneer Fundamental Growth Y
BERCX17.45N/A
N/A
Carillon Chartwell Mid Cap Value I
QQMNX21.87N/A
N/A
Federated Hermes MDT Market Neutral IS
JFEIX40.79-0.30
-0.73%
JPMorgan Europe Dynamic L

ERAS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ERAS has been loosely correlated with OCUL. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if ERAS jumps, then OCUL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ERAS
1D Price
Change %
ERAS100%
-3.32%
OCUL - ERAS
53%
Loosely correlated
+2.81%
XNCR - ERAS
52%
Loosely correlated
-1.62%
EYPT - ERAS
49%
Loosely correlated
+2.29%
RVMD - ERAS
48%
Loosely correlated
-0.04%
IMTX - ERAS
47%
Loosely correlated
N/A
More